Search for Clinical Trial Results
Abdominal Neoplasms - 350 Studies Found
Status | Study |
Active, not recruiting |
Study Name: Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients Condition: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Date: 2012-03-30 Interventions: Drug: Metformin Patients receiving primary surgical debulk |
Completed |
Study Name: Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission Condition:
Interventions: Biological: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21 The injection wil |
Withdrawn |
Study Name: Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC Condition:
Date: 2010-07-14 Interventions: Device: Echocardiogram Echocardiography will be utilized during the procedure to guide fluid management. |
Terminated |
Study Name: Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Condition:
Date: 2009-05-09 Interventions:
|
Active, not recruiting |
Study Name: Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity Condition:
|
Completed |
Study Name: A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer Condition:
Date: 2008-05-19 Interventions: Biological: DCVac-L Subjects will receive three doses of intradermal vaccination with ~5-10 x 106 dendri |
Completed |
Study Name: Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers Condition: Peritoneal Neoplasms Date: 2008-04-23 Interventions: Drug: nanoparticulate paclitaxel This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patien |
Completed |
Study Name: Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer Condition:
Date: 2007-06-19 Interventions:
|
Completed |
Study Name: A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer Condition:
Date: 2007-04-16 Interventions: Drug: pemetrexed 900 mg/m2, intravenous (IV), every 21 days, until disease progression |
Completed |
Study Name: Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin Condition:
Date: 2007-02-15 Interventions:
|